Valuation: Avalo Therapeutics, Inc.

Market Cap 100Cr 86Cr 81Cr 74Cr 139.86Cr 9.49TCr 141.69Cr 947.5Cr 371.85Cr 4.74TCr 374.22Cr 366.09Cr 16TCr P/E 2026 *
-7.63x
P/E 2027 * -6.3x
Enterprise Value 58Cr 50Cr 47Cr 43Cr 81Cr 5.5TCr 82Cr 548.8Cr 215.38Cr 2.75TCr 216.75Cr 212.04Cr 9.15TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.28%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-3.05%
1 week-5.00%
Current month+0.93%
1 month-7.72%
3 months-15.54%
6 months+29.81%
Current year+1.43%
1 week 17.64
Extreme 17.64
19.84
1 month 17.54
Extreme 17.54
20.65
Current year 12.51
Extreme 12.51
24.27
1 year 8.01
Extreme 8.0101
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/06/26 Free

Director

1,080 0.0020%
30/06/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-3.05%-5.00%+121.66%-51.97% 100Cr
-3.25%+12.81%+52.96%+88.86% 6.49TCr
+0.69%+0.96%+29.39%+70.50% 5.41TCr
-2.52%-3.26%-19.29%-8.81% 2.32TCr
+31.15%+27.61%+16.41%+492.20% 2.15TCr
+1.87%+5.08%+29.88%-7.94% 2.13TCr
-0.79%+1.79%+36.31%-26.13% 1.79TCr
-3.37%+19.44%+211.98%+369.13% 1.7TCr
+3.29%+2.09%+17.32%+586.49% 1.5TCr
-6.45%-4.58%+41.62%+163.73% 1.43TCr
Average +1.76%+2.94%+53.82%+167.61% 2.5TCr
Weighted average by Cap. +1.44%+3.62%+43.20%+146.61%

Financials

2026 *2027 *
Net sales - -
Net income -8.57Cr -7.44Cr -6.97Cr -6.37Cr -12Cr -816.57Cr -12Cr -81Cr -32Cr -407.99Cr -32Cr -31Cr -1.36TCr -11Cr -9.58Cr -8.97Cr -8.21Cr -15Cr -1.05TCr -16Cr -104.97Cr -41Cr -525.51Cr -41Cr -41Cr -1.75TCr
Net Debt -42Cr -36Cr -34Cr -31Cr -59Cr -4TCr -60Cr -398.7Cr -156.47Cr -2TCr -157.47Cr -154.05Cr -6.64TCr -31Cr -26Cr -25Cr -23Cr -43Cr -2.91TCr -43Cr -290.09Cr -113.85Cr -1.45TCr -114.57Cr -112.08Cr -4.83TCr
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
06/26/06 $18.45 -2.07% 3,01,115
05/26/05 $18.84 +1.67% 7,34,514
04/26/04 $18.53 +2.66% 11,57,469
03/26/03 $18.05 -1.10% 5,72,280
31/26/31 $18.25 -5.88% 9,23,877
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.84USD
Average target price
44.69USD
Spread / Average Target
+137.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock